- RepliCel Life Sciences (OTCPK:REPCF) announces that it has been awarded two patents in Europe covering RCI-02, its nearest-term commercial asset.
- The device is designed to improve the level of control and precision for intradermal, subcutaneous and intramuscular injections. The company says it is particularly well-suited for injecting cellular products, fillers, hyaluronic acids, fat and collagen.